echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > From November 1st, the price of hundreds of drugs in Shanxi "dived" and it was cheap to buy them

    From November 1st, the price of hundreds of drugs in Shanxi "dived" and it was cheap to buy them

    • Last Update: 2020-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Industry Dynamics" Recently, Shanxi Province pharmaceutical centralized bidding procurement network issued a notice that the center will be on October 31, 2020 at 18:00, focus on adjusting the online purchase price of selected products.
    from November 1, 2020, the relevant medical institutions in Shanxi Province will purchase at adjusted prices.
    November 1st, Shanxi will fully implement the results of the third batch of drugs collected by the state organization, which also means that from November 1st, hundreds of drug prices "dived".
    From November 1st, hundreds of drug prices in Shanxi "dived" (Photo: Pharmaceutical Network) From November 1st, the third batch of 55 drugs purchased by the national organization will land in Taiyuan City, covering chronic disease drugs, anti-infective, anti-tumor and other therapeutic fields, including the commonly used sugar-lowering drug metformin, hypertension drug Capopri, anti-infective drug cephalosporine capsules.
    55 drug prices fell by an average of 53%, a maximum decline of 95%, Taiyuan City 264 medical institutions involved, the first procurement cycle is expected to save patients in Taiyuan City medical costs of 592.13 million yuan.
    it is understood that since December 1, 2019, Shanxi Province has comprehensively promoted the reform of the centralized belt procurement system for pharmaceutical medical supplies, hundreds of commonly used drugs, special effects drugs and some medical supplies prices "diving", welcomed by the masses.
    At present, Shanxi Province has landed the first batch of national organizations, the second batch of drug collection selection results, the official implementation of the province's first batch of drug group alliance collection selection results, and carry out the heart coronary stent and other medical supplies centralized belt procurement work.
    the prices of these "collected" drugs and consumables have been reduced? It is reported that Taiyuan City Second People's Hospital is also Taiyuan City Hospital for the Elderly, a total of 57 kinds of drugs involved in centralized volume procurement, including treatment of high blood pressure, high blood sugar, hyperlipidemia and other common diseases of the elderly imported drugs.
    , for example, the original price of akapo sugar tablets commonly used by diabetics is 64.52 yuan, the current price is only 5.42 yuan.
    the drug's efficacy affected by the price cuts that people are concerned about? Relevant staff said that all the drugs selected are basically the original research drugs (imported drugs) and through the National Drug Administration consistent evaluation of generic drugs, the drug box has a consistent evaluation mark.
    drug selection, the drug regulatory department will strengthen supervision and inspection and product sampling, strengthen full-cycle quality management, to ensure that drug prices do not degrade.
    " in addition to Shanxi, the author was informed that, with the third batch of drugs to land in the country is approaching the deadline, the relevant departments in various provinces and cities have also stepped up the implementation of the policy.
    Such as Shanghai, Beijing, Tianjin, Chongqing, Jiangsu, Liaoning, Inner Mongolia, Ningxia, Hebei, Heilongjiang, Qinghai, Jiangxi, Hubei, Yunnan, Guizhou, Guangdong, Fujian, Hainan, Sichuan and other provinces and cities announced the third batch of mining arrangements.
    can also be seen that in the third batch of 52 varieties involved in national mining, there have been many varieties sold more than 1 billion yuan a year.
    industry estimates that China's pharmaceutical market has entered a full-scale reshuffle as a result of the market size of price cuts due to mining prices approaching 60 billion yuan.
    industry said that as drug collection becomes normal, the marketing costs of related pharmaceutical companies will be significantly reduced, and the proportion of sales will be reduced from 40% to 5% to 10%.
    The so-called drug collection is to volume for price, so that pharmaceutical companies to increase full horsepower production, at the same time, the state has supporting policies to protect drug companies to pay back the cycle, thus forming a virtuous circle, finally let the people get benefits.
    As a hospital staff said, at present, its hospital collection of drugs are basically prescription drugs, used to treat "three high" and other chronic diseases, such patients need long-term medication, the previous heavy financial burden, now the drug price is cheaper, the burden of patients will be reduced a lot.
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.